Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 90–91

HOS-109091 · Präparat HOS-093083

90 Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the 25-O-desacetyl metabolite): recommended dose of rifabutin is AUC: ↑ 5.7-fold 150 mg 3 times per week on set Cmax: ↑ 3.5-fold days (for example Monday- Wednesday-Friday). Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated. It should be kept in mind that the twice weekly dosage of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure. No dose adjustment is needed for Kaletra. Rifampicin Lopinavir: Co-administration of Kaletra with Large decreases in lopinavir rifampicin is not recommended as concentrations may be observed the decrease in lopinavir due to CYP3A induction by concentrations may in turn rifampicin. significantly decrease the lopinavir therapeutic effect. A dose adjustment of Kaletra 400 mg/400 mg (i.e. Kaletra 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin. However, such a dose adjustment might be associated with ALT/AST elevations and with increase in gastrointestinal disorders. Therefore, this co-administration should be avoided unless judged strictly necessary. If this co-administration is judged unavoidable, increased dose of Kaletra at 400 mg/400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring. The Kaletra dose should be titrated upward only after rifampicin has been initiated (see section 4.4). Antipsychotics Lurasidone Due to CYP3A inhibition by The concomitant administration lopinavir/ritonavir, concentrations with lurasidone is contraindicated of lurasidone are expected to (see section 4.3). increase.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) lurasidone (HOS-086148)